High-dose chemotherapy with busulfan and cyclophosphamide and autologous stem cell rescue in patients with Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 7, 2011, Pages 1363-1366

  Lane, Andrew A ^a,b   McAfee, Steven L ^a   Kennedy, Joanne ^a   Dube, Christine ^a   Attar, Eyal C ^a   Ballen, Karen K ^a   Dey, Bimalangshu R ^a   Spitzer, Thomas R ^a   Chen, Yi Bin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BUSULFAN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEFIBROTIDE; DOXORUBICIN; PHENYTOIN; VINBLASTINE;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LETTER; LUNG BIOPSY; LUNG DISEASE; MALE; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; NEUROTOXICITY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEIZURE;

BUSULFAN; CYCLOPHOSPHAMIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MYELOABLATIVE AGONISTS; NEOPLASMS, SECOND PRIMARY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79959583228     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.572324     Document Type: Letter

References (14)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993;341:1051-1054. (Pubitemid 23114397)
3. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomisedtrial. Lancet 2002;359:2065-2071. (Pubitemid 34680969)
4. Kim JG, Sohn SK, Chae YS, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007;40:919-924. (Pubitemid 350048188)
5. Wadehra N, Farag S, Bolwell B, et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006;12:1343-1349. (Pubitemid 44858268)
6. Santos EC, Sessions J, Hutcherson D, Flowers C, Langston A, Waller EK. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation-a similar experience. Biol Blood Marrow Transplant 2007;13:746-747. (Pubitemid 46768001)
7. Ulrickson M, Aldridge J, Kim HT, et al. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non- Hodgkin lymphoma: a single-institution experience. Biol Blood Marrow Transplant 2009;15:1447-1454.
8. Talamo G, Claxton DF, Dougherty DW, et al. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma. Bone Marrow Transplant 2009;44: 157-161.
9. Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007;21:943-960. (Pubitemid 47484144)
10. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 2011 Jan 24. [Epub ahead of print].
11. Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dosereduced BU and CY regimen in older patients with non- Hodgkin's lymphoma. BoneMarrowTransplant 2009;43:37-42.
12. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15: 523-536.
13. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006;12:770-777. (Pubitemid 43899416)
14. Dean RM, Pohlman B, Sweetenham JW, et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 2010;148:226-234.